Anika Therapeutics, Inc. (ANIK) Tops Q3 EPS by 7c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $25.58 -1.24%
EPS Growth %: -63.6%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: -63.6%
Financial Fact:
Total operating expenses: 12.1M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.40, $0.07 better than the analyst estimate of $0.33. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $20.33 million.
For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel (INTC) tops Q1 EPS by 3c; misses on guidance
- Roku stock gains on strong Q1 earnings beat
- SS&C Technologies (SSNC) Tops Q1 EPS by 6c, provides guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
